Exact Sciences Reports Q4 Loss Exceeding Expectations
Exact Sciences Corp. (EXAS) announced a $864.6 million loss in its fourth quarter, translating to a per-share loss of $4.67. Adjusted for non-recurring items, the loss was 6 cents per share, surpassing Wall Street analysts' consensus estimate of 32 cents per share.
The molecular diagnostics company generated $713.4 million in revenue for the quarter. For the full year, Exact Sciences reported a loss of $1.03 billion or $5.59 per share, with revenue reaching $2.76 billion.
Looking ahead, the company projects full-year revenue in the range of $3.03 billion to $3.09 billion.